All the news Showing 8 of 18 articles from: Treatment in cirrhosisGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Albumin reduces complications and improves survival in people with decompensated cirrhosis Liz Highleyman / 08 May 2017 Long-term administration of human albumin was associated with fewer serious complications, less hospitalisation, better quality of life and longer survival for people with decompensated liver cirrhosis, according to a report at the International ... New AbbVie hepatitis C combination cures 99% of people with cirrhosis Keith Alcorn / 21 April 2017 A new pangenotypic direct-acting antiviral combination developed by AbbVie is highly effective in curing hepatitis C in people with cirrhosis, achieving a 99% cure rate after 12 weeks of treatment with minimal side-effects, ... Antibiotic prophylaxis reduces the risk of short-term death in people with decompensated cirrhosis Keith Alcorn / 20 April 2017 Long-term prophylaxis with the antibiotic norfloxacin significantly reduced the incidence of deaths in people with decompensated cirrhosis over a six-month follow-up period, a French randomised trial reported today at the International Liver Congress ... Portal hypertension less likely to fall after HCV treatment when liver stiffness is severe Keith Alcorn / 24 November 2016 Curing hepatitis C infection moderately reduces portal hypertension, but has less impact in people with more severe liver stiffness due to fibrosis, Spanish researchers reported at the 2016 AASLD Liver Meeting last week ... EASL issues new hepatitis C treatment recommendations for all genotypes Liz Highleyman / 26 September 2016 The European Association for the Study of the Liver (EASL) released its latest recommendations on treatment of hepatitis C at a special meeting last Thursday in Paris. The updated guidelines now include highly ... Only treating patients with cirrhosis with DAAs will have limited impact on HCV epidemic in England Michael Carter / 24 May 2016 Targeting new hepatitis C virus (HCV) direct-acting antivirals (DAAs) at patients with cirrhosis will substantially reduce short-term incidence of end-stage liver disease (ESLD) and liver cancer (HCC) in England, according to a model ... Hepatitis C treatment may not be enough to stop the progress of advanced liver disease, or reduce liver transplant need Keith Alcorn / 14 April 2016 Doctors need to have “full and frank” discussions with patients about the potential risks and benefits of using direct-acting antivirals to treat hepatitis C in late-stage liver disease, especially among those waiting for ... Daclatasvir approved for use in HIV/HCV co-infection, decompensated cirrhosis and post-transplant in the EU Keith Alcorn / 03 February 2016 The hepatitis C direct-acting antiviral daclatasvir (Daklinza) has received European Union marketing approval for use in three new populations of people with genotype 1, 3 or 4 hepatitis C infection. The NS5A inhibitor ... ← Prev12Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive